Document:

Java Express, Inc.
(a Nevada Corporation)

Convertible Note

Java Express, Inc.,  a Nevada corporation ("Company") for value received
(summarized more specifically in Exhibit I.) hereby promises to pay to
Dominion World Investments (the "Holder") or its assignee, the sum of  Fifteen
Thousand Dollars ($15,000.00) US, with no interest in consideration of the
conversion right and payable in accordance with the terms and conditions set
forth herein.

1)     Payment Terms:  Principal shall be all due and payable on December 31,
2002. Holder expressly agrees that repayment of the note shall NOT be paid
from proceeds of the company's public offering, and that if additional funds
are not available the holder will convert to equity.

2)     Right to Convert by Holder:  The Holder of this Note shall have the
option to convert only the entire amount and not any portion thereof, of the
principal of this Note into shares of common stock of the Company at a
conversion price as hereinafter provided in Paragraph 3 below.

3)     Conversion Price:  The principal of the Note shall be converted into
common shares of the Company (the "Converted Shares") at a share price equal
to the "bid" price of the Company's common stock on the date of the
conversion, or in the event the Company has no bid price, the principal of
this Note shall be converted into common stock at $.05 per share equaling
three-hundred thousand (300,000) shares of the Company's common stock..

4)     Conversion Date:  The Conversion Date for the Holder of the Note shall
be anytime after December 31, 2002 but  no later than April 25, 2003 (the
Holder's Conversion Period).

5)     Manner of Exercise of Conversion rights:  In order to exercise the
conversion rights of this Note, the Holder must give notice to the Company at
anytime during the Holder's Conversion Period of its intention to exercise

<PAGE>

its conversion rights.  Absent such a notice to the Company, the Holder's
conversion rights shall expire after the expiration of the Holder's Conversion
Period.

6)     Prepayment:  The Company shall have the right to prepay all or any part
of the principal of this Note without penalty.  However, in the event the
Company elects to prepay the Note, the Holder shall have ten (10) days from
the receipt of written notice of this prepayment election to exercise its
conversion rights as set forth above in Paragraph 2.

7)     Default:  In the event the Company fails to pay the principal of this
Note when due, the Holder shall have the option, after providing thirty (30)
days written notice to the Company, to (1) declare the unpaid principal
balance all due and payable or (2) exercise its conversion rights for all of
the unpaid principal as set forth above in Paragraph 2.

8)     Company to Reserve Shares:   The Company shall at all times during the
term of this Note reserve and keep available out of its authorized but
unissued shares, such amount of its duly authorized shares of common stock as
shall be necessary to effect the conversion of this Note.

9)     Notices:  All notices given pursuant to this Note must be in writing
and may be given by (1) personal delivery, or (2) registered or certified
mail, return receipt requested, or (3) via facsimile transmission.

10)    Arbitration:  The parties hereby submit all controversies, claims and
matters of difference arising out of the Note to arbitration in Utah.  This
submission and agreement to arbitrate shall be specifically enforceable.

IN WITNESS WHEREOF, the Company has caused this Note to be executed by its
duly authorized officer.

                                       Java Express, Inc.

                                          /s/ Lance Musicant
Dated:  April 15, 2002             By:   _________________________
                                         Lance Musicant, President<PAGE>
                                                                   Exhibit 10.33

                        CONFIDENTIAL TREATMENT REQUESTED.
    CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN
         SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                LICENSE AGREEMENT

This LICENSE AGREEMENT (this "Agreement") effective as of the 9th day of June
1999, is entered into by and between Permatec Technologie AG, a Swiss
corporation having its place of business at Grienbachstrasse 17, CH-6301 Zug,
Switzerland (hereinafter referred to as "LICENSOR") and SOLVAY Pharmaceuticals
B.V., a Dutch corporation having its place of business at C. J. Van Houtenlaan
36, NL 1381 CP Weesp, The Netherlands (hereinafter referred to as "LICENSEE";
both LICENSOR and LICENSEE hereinafter referred to as "Party" and the "Parties",
respectively).

                                   WITNESSETH:

WHEREAS, LICENSOR is a company active in the field of drug delivery and has in
particular expertise in innovative developments in the area of transdermal and
transmucosal delivery routes; and

WHEREAS, LICENSOR has developed a technology platform known as Combi Gel(TM)
consisting of gel formulations combining Estradiol with a progestative as active
ingredients and owns or has rights to certain patents and owns certain
proprietary know-how related to thereto; and

WHEREAS, LICENSEE is a company which markets pharmaceutical products and is
interested, on the basis of all results, data and related information made
available by LICENSOR to LICENSEE, in having granted the rights to register the
Combi-Gel NETA (as defined below) in the Territory (as defined below), and upon
approval to manufacture, market, distribute and sell the Product (as defined
below) in the Territory; and

WHEREAS, LICENSOR is prepared to grant to LICENSEE under the terms and
conditions set forth hereafter a license under the Patents and Know-How (both as
defined below) to seek registration of the Combi-Gel NETA in the Territory, and,
upon receipt of such approval(s), to manufacture, market, distribute and sell
the Product for use and sale in the Territory.

NOW THEREFORE, for and in consideration of the premises, mutual covenants and
agreements contained herein, and intending to be legally bound hereby, the
Parties hereby agree as follows:

1.   Definitions
     -----------

     For purposes of this Agreement, the terms defined in this Section 1. shall
     have the following meanings:

1.1  "Affiliate" shall mean, with respect to either Party hereto, any
     corporation, partnership or other entity controlled by, controlling or
     under common control with, such Party, with "control"

<PAGE>

     meaning direct or indirect beneficial ownership of more than 50% of the
     voting power of, or more than 50% of ownership interest in, such
     corporation, partnership or other entity.

1.2  "Combi-Gel NETA" shall mean the Combi-Gel containing Estradiol and
     Norethindrone acetate in all concentrations as the sole active ingredients
     for pharmaceutical use with humans developed by LICENSOR prior to the
     effective date of this Agreement first written hereinabove, which is based
     on and/or makes use of and/or is derived by use of the Patents and/or the
     Know-How, and which is described in Appendix A attached hereto.

1.3  "Development Plan" shall mean the plan for the development of the Combi-Gel
     NETA agreed upon by the Parties as attached hereto as Appendix B.

1.4  "Know-How" shall mean all information and data, which are not generally
     known including, but not limited to, patent claims and related information
     not yet disclosed to the public, formulae, procedures, protocols,
     techniques and results of experimentation and testing, which (a) relate to
     a Combi-Gel and/or the Combi-Gel NETA and/or the Product, and (b) are
     necessary or useful to seek Registration for, and/or to manufacture,
     market, distribute and sell, the Product in the Territory, all to the
     extent presently or during the term of this Agreement owned or otherwise
     acquired by, and at the free disposition of, LICENSOR.

1.5  "Major Market Countries" shall mean each of Germany, France and the United
     Kingdom.

1.6  "Net Sales" shall mean the adjusted gross amount invoiced on all sales of
     the Product (including, but not limited to, Hospital Sales, Mail orders and
     Retail Sales), in the Territory, by SOLVAY and/or its Affiliates and/or
     sub-licensee(s) in "bona fide" arm's length sales to independent third
     parties in the trade, as per invoices, less only (i) freight insurance and
     handling charges (when invoiced as additional charges), (ii) returns,
     withdrawals, recalls and allowances actually paid or granted, including
     cash and trade discounts, and (iii) sales taxes, value added taxes, duties
     and other governmental charges (including Federal and state rebates in
     connection with the sale), all in accordance with generally accepted and
     customary trade practices.

1.7  "Patents" shall mean all patents and patent applications filed or having
     presently or in the future legal force in any country of the Territory
     owned by LICENSOR which claim the Combi-Gel NETA and/or the Product, or the
     process to manufacture Combi-Gel NETA and/or the Product, including but not
     limited to the patents and patent applications listed in Appendix C hereto,
     together with all patents that in the future issue therefrom in any country
     of the Territory, including utility, model and design patents and
     certificates of invention, and all divisionals, continuations,
     continuations-in-part, reissues, renewals, extensions, substitutions,
     confirmations or additions to any such patents and patent applications.

1.8  "Product" shall mean the Combi-Gel NETA, for which LICENSEE has been
     granted the Registration.

1.9  "Registration" shall mean the granting of any and all approvals and
     registrations of Product by any Regulatory Authority, including without
     limitation price approval, which are

                                       2

<PAGE>

     required and/or necessary under any applicable law, rule, regulation or
     other governmental order to market, distribute and sell the Product in any
     country of the Territory.

1.10 "Regulatory Authority" shall mean any governmental authority in any country
     of the Territory competent to approve pharmaceutical products for
     manufacturing, marketing, distribution and sale in any country of the
     Territory and/or to approve the price for pharmaceutical products to be
     sold in any country of the Territory.

1.11 "Territory" shall mean all the countries and territories in the world
     except for the countries listed in Appendix D, provided that in the event
     that LICENSEE duly and timely exercises its option under Section 6. below,
     the countries constituting the Extended Territory (as defined in Section
     6.1 below) shall thereafter also be covered by the term Territory.

2.   Grant of License
     ----------------

2.1  LICENSOR hereby grants to LICENSEE the exclusive, sub-licensable right and
     license (hereinafter referred to a the "License") to pursue the development
     in accordance with the Development Plan as required in order to apply for
     Registration(s) for the Combi-Gel NETA, and upon receipt of such
     Registration, to manufacture, market, distribute and sell the Product, in
     the Territory, and to use the Patents and Know-How exclusively for that
     purpose, all in accordance with the provisions contained in this Agreement
     and subject to the payment of the Milestone Payments and the Royalty
     pursuant to Section 5. below.

2.2  For the avoidance of doubt, LICENSEE explicitly acknowledges and agrees
     that the License under the Patents and the Know-How granted hereunder is
     strictly limited to the Combi-Gel NETA (as defined in Section 1.2 above)
     and the Product (as defined in Section 1.6 above), and LICENSOR does not
     grant any license with respect to any other product under its proprietary
     technology platform consisting of gel formulations combining Estradiol with
     a progestative (other than Norethindrone Acetate) as active ingredients. It
     is, however, expressly understood that LICENSEE shall have a right of first
     refusal on any gel formulation developed by LICENSOR on its own combining
     Estradiol with any other progestative. LICENSOR shall offer to LICENSEE the
     same rights for such other combination as set out in 2.1 hereinabove under
     an agreement comparable to this Agreement with the commercial terms and
     conditions to be mutually agreed upon by the Parties in good faith
     negotiations. LICENSEE may exercise such right of first refusal within
     three (3) months following the receipt of the respective offer.

2.3  Notwithstanding any sub-license(s) to be granted by LICENSEE hereunder,
     LICENSEE shall continue to be bound by any and all obligations under this
     Agreement, as if no sub-license was granted, and LICENSEE shall be
     responsible for any and all acts, deeds and omissions of any of its
     sub-licensee(s) hereunder, during the term of this Agreement.

                                       3

<PAGE>

3.   Pharmaceutical and Technical Development
     ----------------------------------------

3.1  Promptly upon execution of this Agreement or receipt of the first Milestone
     Payment referred to in Section 5.1(a) below, which ever is the later,
     LICENSOR shall initiate and thereafter pursue the development steps for the
     Combi-Gel NETA listed in the Development Plan to fall within the
     responsibility of LICENSOR. Upon completion of such development steps,
     LICENSOR shall provide LICENSEE with a copy of all information, data and
     Know-How freely available to LICENSOR necessary and/or useful to allow
     LICENSEE to manufacture or have manufactured the batches of Combi-Gel NETA
     necessary for applying for Registration and for stability testing.

3.2  LICENSEE shall be solely responsible for and undertakes to diligently
     pursue to meet the time-frame set forth in the Development Plan, at its own
     cost, any and all development steps, actions and other activities
     necessary, required or useful to seek and apply for Registration of the
     Combi-Gel(TM) NETA, including without limitation the development steps
     listed in the Development Plan falling within the responsibility of
     LICENSEE, provided that LICENSOR shall provide such reasonable assistance
     and support to LICENSEE with respect to such development steps upon
     LICENSEE's request at the cost and expense of LICENSEE.

3.3  Any and all cost incurred by LICENSOR in connection with the performance of
     the development steps within its responsibility pursuant to the Development
     Program and any assistance and support provided upon request by LICENSOR
     under Sections 3.1 and 3.2 above, shall be reimbursed by LICENSEE on the
     basis of actual cost, plus any and all out-of-pocket expenses, incurred or
     spent by LICENSOR in connection therewith. In the event that LICENSOR, upon
     request or with the consent of LICENSEE, charges any third party with all
     or part of such activities, LICENSEE shall reimburse LICENSOR the cost
     invoiced by such third party plus an amount equal to twenty percent (20%)
     of such invoice amount(s) to cover LICENSOR's workload associated with the
     instruction and supervision of such third party. LICENSOR shall provide
     LICENSEE with respective invoices, which shall be payable by LICENSEE
     within thirty (30) days as of receipt.

3.4  The Parties agree to set up, within thirty (30) days after the mutual
     execution of this Agreement a steering committee (the "Steering
     Committee"), consisting of four (4) qualified members, of which each Party
     may nominate two (2) members. The Steering Committee shall be responsible
     for the supervision of the due and timely development of the Combi-Gel NETA
     pursuant to the Development Plan as provided for in this Section 3.

3.5  The Steering Committee shall meet on a regular basis and upon request of
     any of its members, but at least quarterly, and each Party shall at such
     meetings of the Steering Committee provide the other Party with a written
     update on, and with all results and data generated and achieved under, the
     development steps performed by either Party pursuant to the Development
     Plan. Furthermore, each Party shall promptly inform the other Party in such
     meetings of the Steering Committee of any occurred or envisaged delays in
     the timely performance of its responsibilities under the Development Plan.

                                       4

<PAGE>

3.6  The Steering Committee may amend, alter or change, by resolution mutually
     agreed upon by all of its members, the Development Plan and the time-limits
     for the major development steps contained therein. The Steering Committee
     shall strive to always reach unanimous decisions. In case unanimous
     decisions cannot be reached, the principal officers of LICENSEE and
     LICENSOR or their designees should try to dissolve the dispute. If such
     principal officers of the Parties, despite good faith and diligent
     negotiations, are unable to agree upon a decision, the principal executive
     officers of both LICENSEE and LICENSOR shall convene and attempt in good
     faith to find a solution acceptable to both Parties. In the event that such
     solution may not be found, the principal executive officer of LICENSEE
     shall have the final decision. In the event that the timeframe contained in
     the Development Plan is delayed by any such decision of the principal
     executive officer of LICENSEE by more then twelve (12) months, then
     LICENSOR shall have the right to terminate this Agreement, unless such
     decision is based on scientific and/or technical reasons only.

4.   Registration of the Combi-Gel NETA
     ----------------------------------

4.1  Promptly upon completion of all development steps under the Development
     Plan required therefor, LICENSEE undertakes to initiate and thereafter
     diligently pursue any and all steps and action referred to in Section 3.2
     above as they are necessary and/or required to submit to any competent
     Regulatory Authority in all Major Market Countries of the Territory, at its
     own cost, under its sole responsibility and its own name, request(s) for
     Registration of the Combi-Gel NETA (hereinafter the "Request"); for all
     other countries of the Territory, where Registration of the Combi-Gel NETA
     is commercially viable, LICENSEE shall use all commercially reasonable
     efforts to prepare and submit such Requests. Upon submission of any such
     Request, LICENSEE shall promptly inform LICENSOR thereof, and thereafter,
     LICENSEE shall use all commercially reasonable efforts to prosecute each
     such Request submitted and keep LICENSOR promptly informed on all
     developments related thereto.

4.2  Furthermore, LICENSEE undertakes to inform LICENSOR of all material
     developments and correspondence exchanged with any Regulatory Authority in
     connection with any Request and/or any Registration, including the
     obtention of any Registration by providing a copy of the letter of
     allowance.

5.   License Fees and Royalties
     --------------------------

5.1  As consideration for the License granted by LICENSOR to LICENSEE under this
     Agreement, and in consideration of the development of the Combi-Gel NETA
     prior to the effective date of this Agreement first written above by
     LICENSOR, LICENSEE undertakes to pay to LICENSOR a license fee in the
     aggregate amount of USD 5 million (five million United States Dollars),
     which license fee shall be payable by LICENSEE in four (4) payments (each a
     "Milestone Payment") within thirty (30) days after the occurrence of the
     following events:

                                       5

<PAGE>

     (a)  a first Milestone Payment in the amount of USD 1.0 million
          (one-million United States Dollars) upon execution of this Agreement;
          and

     (b)  a second Milestone Payment in the amount of USD 1.0 million
          (one-million United States Dollars) upon initiation of PhaseIIb/III
          clinical trials; and

     (c)  a third Milestone Payment in the amount of USD 1.0 million
          (one-million United States Dollars) upon the filing of the first
          Request to any Regulatory Authority; and

     (d)  a fourth Milestone Payment in the amount of USD 2.0 million
          (two-million United States Dollars) upon receipt of the first
          Registration for the Product in any one Major Market Country.

5.2  In addition to the Milestone Payments under Section 5.1 above, LICENSEE
     shall pay to LICENSOR as further consideration for the License granted
     hereunder a royalty (the "Royalty") in an amount equal to five percent (5%)
     of Net Sales of Product on a country-by-country basis, during a period (the
     "Royalty Term") of (i) fifteen (15) years as from the first commercial sale
     of Product in each country of the Territory, or (ii) until the expiration
     of the last Patent in such country of the Territory, which ever is the
     later. In the event that during the Royalty Term in any country of the
     Territory (i) no Patent is in force, and/or (ii) a third party Competing
     Product is marketed, then the Royalty rate shall be reduced to *****
     percent (**%) of Net Sales of Product in such country only, whereby
     "Competing Product" shall mean a product being a similar formulation
     containing the same two active ingredients for the identical indications as
     Product, which does not infringe any claim under the Patents.

5.3  All Royalty under Section 5.2 above shall be payable quarterly, and
     LICENSEE shall remit to LICENSOR within six (6) weeks after the end of each
     calendar quarter, for the first time after the fifth Milestone Payment
     under Section 5.1(e) became due, the amount of Royalty due with respect of
     Net Sales achieved in the preceding calendar quarter. LICENSEE shall
     deliver to LICENSOR, along with such remittance of Royalty payment, a
     detailed statement on a country-by-country basis (hereinafter referred to
     as the "Royalty Report") of the Net Sales of Product achieved and the
     applied Royalty rate under Section 5.2, to which the Royalty payment
     relates. All Royalty Reports shall be prepared in accordance with generally
     accepted accounting principles consistently applied from applicable period
     to period and shall be certified by an officer of LICENSEE as being so
     prepared, true, accurate and correct.

5.4  Unless otherwise agreed by the Parties in writing, all payments under this
     Section 5. shall be made in United States Dollars and to such place or
     account as LICENSOR reasonably requests from time to time in writing. To
     the extent that Net Sales of Product will be calculated in any currency
     other than United States Dollars, LICENSEE shall convert calculation of
     such Net Sales from such other currency into United States Dollars at the
     average of the selling/buying exchange rate published by the Wall Street
     Journal Europe at the last day of the calendar quarter during which such
     Net Sales were made.

                                       6

***** - Denotes portions omitted pursuant to a request for confidentiality under
Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with
the omitted information intact has been filed separately with the Securities and
Exchange Commission.

<PAGE>

6.   Extension of Territory
     ----------------------

6.1  LICENSOR hereby grants LICENSEE the right and option (the "Option") to
     extend the Territory as defined in the first sentence of Section 1.11 above
     to include also the country of Canada (the "Extended Territory").

6.2  LICENSEE may exercise its option under Section 6.1 by written notice at no
     cost at any time during the first three (3) months (the "Option Period")
     after the effective date first written above. During such Option Period,
     LICENSEE shall evaluate with the Regulatory Authority in Canada whether any
     additional and/or specific requirements for the filing of a Request and/or
     for the Registration in Canada are to be met.

6.3  In the event that LICENSEE shall duly and timely exercise the Option, then
     the Parties shall negotiate in good faith and mutually agree upon the
     increase of Milestone Payments under Section 5.1 above as additional
     consideration for the inclusion of the Extended Territory. In the event
     that LICENSEE shall not duly and timely exercise the Option, then the
     Option granted under this Section 6. shall lapse and fall away, and
     LICENSOR shall retain any and all rights to and interest in the Combi-Gel
     NETA and the Product in the Extended Territory.

7.   Inspection and Audit
     --------------------

7.1  During the term of this Agreement and during a period of twelve (12) months
     after its expiration or termination for any reason, upon the written
     request of LICENSOR and not more than once each calendar year, LICENSEE
     shall permit an independent certified public accountant selected by
     LICENSOR and acceptable to LICENSEE (not to be withheld or delayed
     unreasonably) to have access during regular business hours to such of the
     records of LICENSEE and its Affiliates and sub-licensee(s) as may be
     reasonably necessary to verify the accuracy of the Royalty Reports for any
     year ending not more than thirty-six (36) months prior to the date of such
     audit request. The accounting firm shall disclose to LICENSOR only whether
     the Royalty Reports and records of LICENSEE and the amount of Royalty
     actually paid are correct or not and the specific details concerning any
     discrepancies; no other information shall be shared. The Parties agree to
     accept such written audit report as final and binding upon them.

7.2  If such accounting firm concludes that additional Royalty were owed during
     any such period audited, LICENSEE shall pay within fourteen (14) days the
     difference between the Royalty paid and the Royalty due as of the date
     LICENSOR delivers to LICENSEE such accounting firm's written report so
     concluding. The fees and expenses charged by such accounting firm with
     respect to any such audit shall be paid by LICENSOR, provided however, that
     if any such audit discloses that Royalty payable by LICENSEE for any
     audited period are more than one-hundred ten percent (110%) of the Royalty
     actually paid for such period, then LICENSEE shall pay all reasonable fees
     and expenses charged by such accounting firm with respect to such audit.

                                       7

<PAGE>

8.   Proprietary Right and Patents
     -----------------------------

8.1  The LICENSOR shall retain title to and full ownership in the Patents and
     the Know-How including, but not limited to, any and all developments and
     inventions related thereto, if any (hereinafter collectively referred to as
     "LICENSOR IPR").

8.2  LICENSEE shall not, directly or indirectly through its officers, directors,
     employees, agent, affiliates, customers or other controlled or associated
     third parties, acquire any proprietary interest in or other right to
     LICENSOR IPR, other than provided in this Agreement.

8.3  LICENSOR shall use all commercially reasonable efforts, at its own cost, to
     prepare, prosecute and maintain all patent applications and patent
     constituting Patents, and shall keep LICENSEE fully and promptly informed
     on any developments or changes relating thereto. If the LICENSOR decides
     not to further prosecute any patent application constituting Patents,
     LICENSOR shall promptly inform LICENSEE of such decision in writing, and
     the Parties shall, upon LICENSEE's written request, meet to discuss any
     appropriate action.

8.4  If LICENSEE becomes aware of (i) any product or activity of any kind that
     involves or may involve an infringement or violation of LICENSOR IPR, or
     (ii) any third-party action, claim or dispute (including, but not limited
     to, actions for declaratory judgment alleging the invalidity or
     non-infringement) based upon or arising out of LICENSOR IPR, then LICENSEE
     shall promptly notify LICENSOR in writing of any such infringement,
     violation, action, claim or dispute. LICENSOR undertakes to take and
     control the commercially feasible and appropriate, as determined at
     LICENSOR's sole discretion, course of action to enforce, or otherwise abate
     the infringement of, or defend third-party actions regarding LICENSOR IPR.
     LICENSOR shall keep LICENSEE regularly informed on any such action. Where
     and to the extent necessary to recover damages suffered by LICENSEE by any
     such infringement, LICENSEE shall be made, upon its written request and
     where possible, an additional party to any such action taken by LICENSOR.

8.5  LICENSEE shall retain title to and ownership of all results and data
     generated and achieved by LICENSEE hereunder and the Registration(s) for
     the Product in the Territory, subject to Sections 8.6, 10.4(iv) and 10.7
     below. LICENSEE shall be responsible for and shall control, at its own
     cost, the preparation, prosecution and maintenance of all Registration(s)
     and shall keep LICENSOR fully and promptly informed on any developments or
     changes relating thereto. During the term of this Agreement, LICENSEE
     shall, at its sole cost, take all steps necessary to prosecute and/or
     maintain all Registrations.

                                       8

<PAGE>

8.6  LICENSOR shall be entitled to use any and all data and results, including
     without limitation clinical data, generated by LICENSEE under Section 3.2
     above to apply or have applied for and obtain Registrations for Product in
     any country outside the Territory, provided that if such Registration of
     Product is obtained by or on behalf of LICENSOR, than the Parties shall, in
     good faith negotiations, mutually agree on an adequate consideration to
     LICENSEE for such use of the results and data, which consideration shall
     reasonably reflect the commercial benefit of such use to LICENSOR in such
     country(ies).

9.   Confidentiality
     ---------------

9.1  LICENSEE shall maintain in confidence all Know-How and other information of
     LICENSOR disclosed by LICENSOR hereunder (the "Confidential Information"),
     and shall not use, disclose or grant the use of any of the Confidential
     Information except on a need-to-know basis to its Affiliates and
     sub-licensee(s) and the respective directors, officers, employees, agents,
     consultants, clinical investigators or other permitted contractors, to the
     extent such disclosure is reasonably necessary in connection with
     LICENSEE's activities as expressly authorised by this Agreement. To the
     extent that disclosure is authorised by this Agreement, prior to
     disclosure, LICENSEE shall obtain agreement in writing of any such person
     to hold in confidence and not make e use of the Confidential Information
     for any purpose other than authorised by this Agreement. LICENSEE shall
     notify LICENSOR promptly upon the discovery of the unauthorised use or
     disclosure of any Confidential Information.

9.2  The obligations of confidentiality and non-use in Section 9.1 above shall
     not apply to the extent that (a) LICENSEE (i) is required to disclose
     information by law, regulation or order of a governmental agency or a court
     of competent jurisdiction, or (ii) is required to disclose information to
     any Regulatory Authority for purposes of obtaining Registrations, provided
     in each case that LICENSEE shall provide LICENSOR with a copy of the
     Confidential Information submitted, or (b) LICENSEE can demonstrate that
     (i) the disclosed information was public knowledge, other than as a result
     of actions of LICENSEE or its Affiliates or sublicensee(s) or their
     respective directors, officers and employees in violation hereof, or (ii)
     the disclosed information was rightfully known by LICENSEE as shown by its
     written records prior to the date of disclosure to it by LICENSOR
     hereunder, or (iii) any Confidential Information was independently
     developed by LICENSEE without any use of Confidential Information as shown
     by its written records.

9.3  The confidentiality obligations under this Section 9. shall be effective
     during the entire term of this Agreement and for a period of five (5) years
     after the expiration or earlier termination hereof. LICENSOR shall be
     entitled to injunctive remedies and relief against LICENSEE and any third
     parties for any breach or threatened breach of the confidentiality
     obligations under this Section 9. In the event of a breach of the
     confidentiality obligations under this Section 9. by LICENSEE or its
     Affiliates or sub-licensee(s) and their respective directors, officers,
     employees or any other person who

                                       9

<PAGE>

     were given access to the Confidential Information by LICENSEE, LICENSOR
     shall be entitled to receive from LICENSEE any and all actual costs and
     damages caused by any such breach.

9.4  The confidentiality and non-use obligations contained in this Section 9.
     shall apply mutatis mutandis to LICENSOR with respect to any confidential
     information and data relating to LICENSEE's business affairs, trade secrets
     and commercial plans disclosed to LICENSOR during the term of this
     Agreement, if any.

10.  Term and Termination
     --------------------

10.1 This Agreement shall enter into force as of the effective date first
     written herein above and shall, unless earlier terminated in accordance
     with the provisions of Section 10.2 below, expire on a country-by-country
     basis upon expiration of the Royalty Term in each country of the Territory.
     Upon expiration of the Royalty Term in each country of the Territory
     pursuant to this Section 10.1 and payment by LICENSEE of all Milestone
     Payments and Royalties due hereunder, the License granted hereunder shall
     be deemed a perpetual, fully paid-up and royalty-free license for each such
     country of the Territory.

10.2 At any time during the term of this Agreement, this Agreement may be
     terminated by giving written notice to that effect, as follows:

     (a)  by either Party, if the other Party is in default or in breach of any
          term or provision hereof and such default or breach continues and is
          not remedied within thirty (30) days upon the other Party's written
          request to remedy such default or breach; or

     (b)  by either Party, if the other Party goes into liquidation, voluntarily
          or otherwise, other than for the sole purpose or reorganization, or
          goes into bankruptcy or makes an assignment for the benefit of
          creditors, or in the event of a receiver being appointed of the other
          Party's property or parts thereof; or

     (c)  by either Party (the "Notified Party") within ninety (90) days upon
          receipt of the written notice of the other Party (the "Notifying
          Party") that the effective control of all or a substantial part
          (greater than fifty percent 50%) of the pharmaceutical business of
          such Notifying Party, whether by sale of stock or assets, passes into
          the hands of a pharmaceutical competitor of the Notified Party, and
          the Notified Party can reasonably demonstrate to the Notifying Party
          that continuation of this Agreement would materially affect and
          negatively influence its business; or

     (d)  by LICENSOR in case of a breach by LICENSEE of any of the
          confidentiality provisions of Section 9 above; or

     (e)  by LICENSOR, if LICENSEE does not file a Request for Registration in
          any Major Market Country(ies) of the Territory within six (6) months
          after receipt of

                                       10

<PAGE>

          the first Registration by a Regulatory Authority, with respect to
          those Major Market Countries only where no Request has been timely
          filed, and in each case only if LICENSEE does not file such Request
          within one (1) month after LICENSOR's written request to do so,
          subject to Section 12.6 below; or

     (f)  by LICENSOR, if LICENSEE does not file a Request for Registration in
          any country(ies) of the Territory not being a Major Market Country
          within six (6) months after receipt of the first Registration of a
          Regulatory Authority in a Major Market Country (or the reference
          country under the mutual recognition procedure of the European Union,
          if applicable), with respect to those countries only where no Request
          has been timely filed, and in each case only if LICENSEE does not file
          such Request within one (1) month after LICENSOR's written request to
          do so, subject to Section 12.6 below; or

     (g)  by LICENSOR, if any Regulatory Authority has finally denied the
          Registration (or any material part thereof) for the Product in any
          country of the Territory, with respect to such country or countries
          only; or

     (h)  by LICENSOR, if LICENSEE ceases to market and sell Product in any
          country of the Territory, and the marketing and sale is not resumed by
          LICENSEE within two (2) month as of LICENSOR's respective notice, with
          respect to such country or countries only.

10.3 The termination of this Agreement shall be without prejudice to any rights
     and obligations of either Party accrued prior to the effective date of such
     termination. LICENSEE shall forthwith make all payments due and outstanding
     to LICENSOR at the date of termination. Except as explicitly otherwise
     stated in this Agreement, LICENSOR shall not be obliged to refund upon
     termination of this Agreement to LICENSEE any payments, including without
     limitation the Milestone Payments or the extension fee under Section 6.
     above, made by LICENSEE to LICENSOR prior to such termination pursuant to
     the provisions of this Agreement.

10.4 In the event of termination of this Agreement for whatsoever reason, then
     the License shall immediately be terminated and LICENSEE shall (i)
     immediately refrain from using directly or indirectly in any way the
     Patents, Know-How and Confidential Information, and (ii) return to LICENSOR
     all materials, documentation, information, data and other things furnished
     by LICENSOR in connection with this Agreement, including without limitation
     any and all Confidential Information and LICENSOR IPR, together with all
     copies thereof in LICENSEE's possession or under its control, which were
     achieved, produced or received hereunder, all free of any charge, and (iii)
     deliver to LICENSOR any and all studies, data, results and protocols
     achieved, produced or gained by LICENSEE in performing the development
     steps set forth in the Development Plan, all free of any charge, and (iv)
     transfer any and all Registrations for Product to LICENSOR or any third
     party designated by LICENSOR in writing, if any, and to execute any
     document and perform any other act necessary or required for that purpose,
     all free of any cost to LICENSOR, subject to Sections 10.5 and 10.7 below.
     LICENSOR shall have the

                                       11

<PAGE>

     right, but no obligation, to use, at its sole discretion, any and all such
     material, including without limitation Registrations, if any, for its own
     purposes and benefit.

10.5 In the event only that this Agreement is terminated by LICENSEE pursuant to
     Section 10.2(a) above, then LICENSOR shall be obliged to reimburse to
     LICENSEE all cost and expenses directly incurred by LICENSEE to generate,
     acquire or receive the studies, data, results, protocols and Registrations
     (if any) to be delivered by LICENSEE to LICENSOR pursuant to Sections
     10.4(iii) and l0.4(iv) above.

10.6 In the event that any termination hereunder is limited to one or more
     countries of the Territory as provided for in Sections 10.2(e), (f), (g)
     and (h) above, than the effects of termination shall only apply to such
     country or countries of the Territory, but shall not affect in any way the
     validity of this Agreement with respect to any other country of the
     Territory.

10.7 In the event that the Agreement with respect to any country or countries of
     the Territory, for which Registration of Product has been obtained, is
     terminated pursuant to Section 10.2(i) above, then LICENSEE shall be
     obliged to transfer such Registration(s) in such country(ies) of the
     Territory to LICENSOR or any third party(ies) designated by LICENSOR,
     against a mutually acceptable consideration payable by LICENSOR (or such
     third party) to LICENSEE, which consideration shall be negotiated in good
     faith between the Parties.

10.8 Notwithstanding anything contained in Sections 10.4 and 10.5 above, the
     termination of this Agreement by either Party shall not limit remedies
     which may be otherwise available in law or equity to either Party.

11.  Representations and Warranties
     ------------------------------

11.1 LICENSOR represents and warrants that it has all rights regarding Patents,
     Know-How and the Combi-Gel NETA necessary to grant the License hereunder.
     Notwithstanding the preceding sentence, LICENSOR does not assume any
     responsibility and makes no representation or warranty that the performance
     of this Agreement, the Combi-Gel NETA and/or the Product, do not infringe
     any third party's patents, patent applications or other intellectual
     property rights. Furthermore, LICENSOR makes no representation or warranty,
     express or implied, with respect to the Combi-Gel NETA and/or the Product
     and/or the Know-how, including without limitation, any warranty of
     completeness, accuracy, merchantability or fitness for a particular purpose
     thereof, in particular with respect to the intended purpose of successful
     Registration in any country of the Territory.

     Nothing in this Agreement shall be construed as a representation made, or
     warranty given, by LICENSOR that any patent will issue based upon any
     pending patent application encompassed by the term Patents, and that any
     patent encompassed by the term Patents issued or which issues will be valid
     or enforceable.

                                       12

<PAGE>

     LICENSOR assumes no liability or responsibility hereunder for any damages
     caused to LICENSEE, third parties, animals and/or the environment by the
     manufacturing, marketing or use of the Combi-Gel NETA and/or the Product or
     the active ingredients contained therein, except to the extent that any
     such damage is attributable to the gross negligence or willful misconduct
     of LICENSOR in performing its obligations hereunder.

11.2 LICENSEE represents and warrants to use all commercially reasonable efforts
     to perform and pursue all steps and actions required for, and apply for and
     pursue the Registration for Product in each country of the Territory within
     the time-limits set forth in the Development Plan, and, upon such
     Registration(s) being granted, to market and sell Product throughout all
     Major Market Countries, and to use all commercially reasonable efforts to
     that effect in all other countries of the Territory, during the term of and
     in accordance with this Agreement.

     Furthermore, LICENSEE represents and warrants that it shall at all times
     comply with and respect any and all applicable laws, rules, regulations and
     orders, including all terms and conditions of the Registration(s) (if any),
     when manufacturing, distributing, marketing and selling the Product in any
     country of the Territory.

11.3 Subject to the specific representations and warranties given in this
     Section 11., and further subject to anything to the contrary contained in
     this Agreement, either Party shall, as to third parties, be indemnified and
     held harmless by the other Party from and against any and all losses,
     liabilities and damages (including attorney's fees) arising from any claim,
     action or other proceedings by any third party relating to any acts or
     omission of the other Party, its directors, officers, employees or agents,
     or any breach of the representations and warranties given by either Party
     in this Section 11., or the negligence or willful misconduct of such other
     Party, its directors, officers, employees or agents in performing any of
     its obligations under this Agreement.

12.  Miscellaneous Provision
     -----------------------

12.1 Entire Agreement: The terms, covenants, conditions and provisions contained
     in this Agreement, including its Appendices referred to herein and together
     with the Supply Agreement, constitute the total and complete agreement of
     the Parties regarding the subject matter hereof and supersede all prior
     understandings and agreements hereto made, and there are no other
     representations, understandings or agreements relating to the subject
     matter hereof. The provisions of this Agreement may not be waived, altered,
     amended or repealed in whole or in part except by the written consent of
     both Parties to this Agreement.

12.2 Assignment: This Agreement may not be assigned or otherwise transferred,
     nor except as expressly provided hereunder, may any right or obligation
     hereunder be assigned or transferred by either Party without the prior
     written consent of the other Party to any third party other than an
     Affiliate of such Party. Any permitted assignee shall assume all

                                       13

<PAGE>

     obligations of its assignor under this Agreement or under the respective
     rights or obligations actually assigned.

12.3 Notices: Any consent, notice or report required or permitted to be given or
     made under this Agreement by one Party to the other shall be in English and
     in writing, delivered personally or by international courier service or by
     facsimile (promptly confirmed by personal delivery or international courier
     service) addressed to the other Party at its address indicated below, or to
     such other address as shall have been notified in writing to the sending
     Party by the receiving Party from time to time, and shall take effect upon
     receipt by the addressee.

     If to LICENSOR:                   Permatec Technologie AG
                                       c/o Permatec Pharma AG
                                       Hardstrasse 18
                                       CH-4132 Muttenz, Switzerland

     with copy to:                     Rinderknecht Klein & Stadelhofer
                                       Beethovenstrasse 7
                                       CI-I-8022 Zurich, Switzerland

     If to LICENSEE:                   Solvay Pharmaceuticals B.V.
                                       C. J. Van Houtenlaan 36
                                       NL-1381CP Weesp, The Netherlands

12.4 Independent Contractors: It is expressly agreed that the Parties shall be
     independent contractors and that the relationship between the Parties shall
     not constitute a partnership, joint venture or agency. Neither Party shall
     have the authority to make any statements, representations or commitments
     of any kind, or to take any action, which shall be binding on the other
     Party, without the prior written consent of the other Party to do so.

12.5 Severability: Each Party hereby acknowledges that it does not intend to
     violate any public policy, statutory or common laws, rules, regulations,
     treaty or decision of any government agency or executive body thereof of
     any country or community or association of countries. Should one or more
     provisions of this Agreement be or become invalid, the Parties hereto shall
     substitute, by mutual consent, valid provisions for such invalid provisions
     which valid provisions in their economic effect are sufficiently similar to
     the invalid provisions that it can be reasonably assumed that the parties
     would have entered into this Agreement with such valid provisions.

12.6 Force Majeure: Neither Party hereto shall be held liable or responsible to
     the other Party nor be deemed to have defaulted under or breached this
     Agreement for failure or delay in fulfilling or performing any term of this
     Agreement when such failure or delay is caused by or results from causes
     beyond the reasonable control of the affected Party, including but not
     limited to fire, floods, embargos, war, acts of war (whether war be
     declared or not), insurrections, riots, civil commotions, strikes, lockouts
     or other labour disturbances,

                                       14

<PAGE>

     acts of God, omissions or delays in acting by any governmental authority or
     the other Party hereto.

12.7 Headings: The titles and headings used in this Agreement are intended for
     convenience only and shall not in any way affect the meaning or
     construction of any provision of this Agreement.

12.8 Waiver: The waiver by either Party hereto of any right hereunder or the
     failure to perform or of a breach by the other Party shall not be deemed a
     waiver of any other right hereunder or of any other breach or failure by
     said other Party whether of a similar nature or otherwise.

12.9 Counterparts: This Agreement may be executed in two or more counterparts,
     each of which shall be deemed an original, but all of which together shall
     constitute one and the same instrument.

13.  Dispute Resolution and Arbitration
     ----------------------------------

13.1 In the event of any dispute arising between the Parties concerning this
     Agreement, LICENSOR and LICENSEE agree that in the first place they shall
     meet for good faith discussions in an attempt to negotiate an amicable
     solution.

13.2 The Parties agree that any dispute, controversy or claim arising out of or
     relating to this Agreement, or the interpretation, breach or enforcement
     thereof, which cannot be amicably resolved pursuant to Section 13.1 above
     within two (2) months as from the first appearance of such dispute, shall
     be settled by arbitration under the Rules of Arbitration of the
     International Chamber of Commerce (the "Rules") by a panel of three (3)
     arbitrators selected in accordance with the Rules. Any arbitration
     proceeding commenced by either Party shall be held in the Paris, France,
     and the language governing any such proceedings shall be English. The
     decision of the arbitrators shall be final and binding upon the Parties,
     and judgment upon the decision by the arbitrators may be entered in any
     court of competent jurisdiction, and execution may be had thereon. The
     expense of such arbitration, including attorneys' fees, shall be allocated
     between the Parties as the arbitrators may decide and as the claims and
     interests of each party may prevail.

13.3 Notwithstanding anything contained in Section 13.2 above, either Party may
     seek preliminary or injunctive measures or relief in any competent court
     having jurisdiction.

14.  Applicable Law
     --------------

     The Parties hereby agree that this Agreement, all transactions executed
     hereunder and all relationship between the Parties in connection therewith,
     shall be construed under and be governed by the laws of Switzerland without
     reference to the conflict of law principals thereof, and shall not be
     governed by the United Nations Convention on Contracts for the
     International Sale of Goods (the Vienna Convention of April 11, 1980).

                                       15

<PAGE>

IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the
date first written above.

     The LICENSOR:                          Permatec Technologie AG

                                            /s/  J. Gonella
     ------------------------------         ------------------------------------
     (Place and Date)                       by:  Dr. J. Gonella
                                            its: President

     The LICENSEE:                          SOLVAY Pharmaceuticals B. V.

     Weesp,  9/6/99                         /s/  E. Koopmans
     ------------------------------         ------------------------------------
     (Place and Date)                       by:  E. Koopmans
                                            its: President

                                       16

<PAGE>

                                   Appendix A

                          Description of Combi-Gel NETA
                             pursuant to Section 1.2

Combi Gel(TM) NETA is a transparent, non-staining gel to be applied once-a-day
in postmenopausal women.

Based on Permatec's Combi Gel(TM)Technology, it delivers transdermal levels of
two hormones: 17-beta Estradiol and Norethindrone Acetate.

Combi Gel(TM) NETA is protected by different patents on the Combi Gel(TM)
Technology.

                                       17

<PAGE>

                                   Appendix B

                                Development Plan
                             pursuant to Section 1.3

Tentative Development Plan:  (activities to be done by Solvay Pharmaceuticals
--------------------------   unless mentioned differently)

Assumptions
-----------

1.       ********
2.       ********
3.       ********

Preclinical
-----------

-        ********
-        ********
-        ********
-        ********

Pharmaceutical Development
--------------------------

Manufacturing:                                             responsibility:
                                                           ---------------
-        ********                                                       P
-        ********                                                       S
-        ********                                                       S
-        ********                                                       S

Analytical methods:
-        ********                                                       S
-        ********                                                       S
-        ********  ******** ********* ********* *******
-        ********                                                       P
-        ********                                                     S/P
-        ********                                                     S/P

Stability:
-        ********                                                       P
-        ********                                                       S

********:                                                               P

********:                                                               S

                                       18

***** - Denotes portions omitted pursuant to a request for confidentiality under
Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with
the omitted information intact has been filed separately with the Securities and
Exchange Commission.

<PAGE>

********:                                                               S

********:                                                               P

********:                                                               S

S = Solvay
P = Permatec

Phase 1*

********:

-        ********
-        ********
-        ********
-        ********

Phase II / III*

********:

-        ********
-        ********
-        ********

* Planning of the milestones, assuming a start of the program on ********
  -----------------------------------------------------------------------

1.       End of phase I                     :                    ******
2.       End of phase II/III                :                    ******
3.       ********                           :                    ******
4.       ********                           :                    ******

                                       19

***** - Denotes portions omitted pursuant to a request for confidentiality under
Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with
the omitted information intact has been filed separately with the Securities and
Exchange Commission.

<PAGE>

                                   Appendix C

                                 List of Patents
                             pursuant to Section 1.6

Combi GEL(TM) Technology is covered by a patent having the following title:

"A novel composition for transdermal administration of an estrogen, a progestin
or a mixture thereof".

This patent has been applied in the following countries:

Italy:                      -  Granted on 07/04/98
-----                       -  Patent Number: 1.283.102

South Africa:               -  Granted on 25/03/98
------------                -  Patent Number: 97/4981

New Zealand:                -  Granted on 19/03/98
-----------                 -  Patent Number: 328021

Europe:                     -  Date of Application: 04/06/97
------                      -  Application Number: 97108989.1
                            -  Date of Publication: 10/12/97
                            -  Publication Number: EP 0811 381

USA:                        -  Date of Application: 05/06/97
---                         -  Application Number: 08/869,982
                            -  Notice of Allowability received in November 1998

Canada:                     -  Date of Application: 05/06/97
------                      -  Application Number: 2,207,144

Australia:                  -  Date of Application: 05/06/97
---------                   -  Application Number: 24729/97

Japan:                      -  Date of Application: 05/06/97
-----                       -  Application Number: 9-185695
                            -  Date of Publication: 17/03/98
                            -  Publication Number: 10-7235 1

South Korea:                -  Date of Application: 04/06/97
-----------                 -  Application Number: 97-23 704

                                       20

<PAGE>

Taiwan:                     -  Date of Application: 06/06/97
------                      -  Application Number: 86107807

Argentina:                  -  Date of Application: 06/06/97
---------                   -  Application Number: P970102497

                                       21

<PAGE>

                                   Appendix D

                         Countries included in Territory
                            pursuant to Section 1.10

The term Territory as defined in Section 1.10 shall include all the countries
and territories in the world with the exception of:

1.   USA

2.   Canada (subject to the Option under Section 6. of the Agreement)

3.   Japan

4.   Korea

                                       22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]